ARR-002 / Aarvik Therap, ArriVent - LARVOL DELTA

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma (Businesswire) - "Aarvik Therapeutics...is pleased to announce that its collaboration partner ArriVent BioPharma, Inc. has exercised the option to exclusively license the collaboration program. As part of the research collaboration agreement entered into between Aarvik and ArriVent on December 21, 2021, Aarvik has been responsible for discovery and preclinical development of a novel ADC molecule that relies on the unique modular platform developed by Aarvik. ArriVent will be responsible for clinical development and commercialization."

Licensing / partnership • Oncology